NCT06275126 Optimizing Surgical Decisions in Young Adults With Breast Cancer
| NCT ID | NCT06275126 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Breast Cancer Stage 0 |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2024-03-13 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2024-03-13 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded.
Eligibility Criteria
Inclusion Criteria: * Female aged 18-44 * New diagnosis of Stage 0, 1, 2, or 3 unilateral breast cancer * English or Spanish speaking Exclusion Criteria: * Diagnosis of de novo Stage 4 breast cancer * Recurrent early-stage breast cancer * Bilateral breast cancer
Contact & Investigator
Shoshana Rosenberg, ScD, MPH
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT06275126 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 44 Years, studying Breast Cancer Stage 0. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06275126 currently recruiting?
Yes, NCT06275126 is actively recruiting participants. Contact the research team at shr4009@med.cornell.edu for enrollment information.
Where is the NCT06275126 trial being conducted?
This trial is being conducted at New Haven, United States, Boston, United States, New York, United States, Durham, United States.
Who is sponsoring the NCT06275126 clinical trial?
NCT06275126 is sponsored by Weill Medical College of Cornell University. The principal investigator is Shoshana Rosenberg, ScD, MPH at Weill Medical College of Cornell University. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.